Apriem Advisors Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Apriem Advisors reduced its stake in AbbVie Inc by 4.61% during the most recent quarter end. The investment management company now holds a total of 89,647 shares of AbbVie Inc which is valued at $5.6 Million after selling 4,333 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.AbbVie Inc makes up approximately 2.20% of Apriem Advisors’s portfolio.

Other Hedge Funds, Including , Symphony Asset Management boosted its stake in ABBV in the latest quarter, The investment management firm added 4,692 additional shares and now holds a total of 70,382 shares of AbbVie Inc which is valued at $4.4 Million. AbbVie Inc makes up approx 0.84% of Symphony Asset Management’s portfolio.Neuberger Berman Group boosted its stake in ABBV in the latest quarter, The investment management firm added 40,790 additional shares and now holds a total of 705,904 shares of AbbVie Inc which is valued at $44.1 Million. AbbVie Inc makes up approx 0.06% of Neuberger Berman Group’s portfolio.Alphamark Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 1,075 additional shares and now holds a total of 4,200 shares of AbbVie Inc which is valued at $262,542. AbbVie Inc makes up approx 0.14% of Alphamark Advisors’s portfolio.Bartlett reduced its stake in ABBV by selling 8,051 shares or 4.91% in the most recent quarter. The Hedge Fund company now holds 156,051 shares of ABBV which is valued at $9.8 Million. AbbVie Inc makes up approx 0.49% of Bartlett’s portfolio.

AbbVie Inc opened for trading at $61.08 and hit $61.47 on the upside on Wednesday, eventually ending the session at $61.22, with a gain of 0.86% or 0.52 points. The heightened volatility saw the trading volume jump to 58,57,619 shares. Company has a market cap of $99,015 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.